Vaccibody reports promising preclinical data with a second-generation COVID-19 vaccine and announces its infectious disease strategy

- *Vaccibody demonstrates promising pre-clinical data with its second-generation COVID-19 vaccine candidate, VB10.COV2*
- *VB10.COV2 induces rapid, strong and long-lasting neutralizing antibodies and multifunctional, dominant CD8+ T cell and Th1 CD4+ T cell responses in mice after a single dose*
- *Vaccibody will present the pre-clinical data and its broader infectious disease strategy during a webcast on Friday December 11 at 10 am CET*

Oslo, Norway, December 10, 2020 – Today, Vaccibody AS, a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel vaccines and immunotherapies, published promising pre-clinical data with its COVID-19 vaccine candidate, VB10.COV2, in mice. The manuscript describing these preclinical data is available on the preprint server bioRxiv (see below for relevant link).

President & Chief Scientific Officer of Vaccibody, Agnete Fredriksen said: "Vaccibody announced the initiation of its expansion into infectious diseases in April 2020. Based on preclinical data with a number of pathogens we expected the platform technology was well suited for developing vaccines against pathogens with pandemic potential. We are very excited about the supportive data generated with VB10.COV2 and look forward to explore further the potential of this second generation COVID-19 vaccine and to use the same platform for other infectious diseases with high unmet needs."

The SARS-CoV-2 virus has caused over 62 million cases of COVID-19 disease and over 1.5 million deaths. A safe and effective vaccine able to prevent transmission and provide persistent protection from the disease is a cornerstone in the global strategy to mitigate this pandemic. An ideal vaccine, as described by WHO, would be given as a single dose regimen, ensuring persistent protection in all age groups through the generation of rapid and long-lasting neutralizing antibodies and a balanced CD4+ and CD8+ T cells response. Ideally, the vaccine would be developed on a platform enabling rapid adaptation to antigen changes, be easy to manufacture at large scale, and be stable at +2-8°C.

Director Infectious Diseases, Gunnstein Norheim commented: "We believe Vaccibody's innovative vaccine candidate has the potential to address unmet needs as outlined by the WHO's target product profile for vaccines against COVID-19. Our preclinical data support a rapid onset of both neutralizing antibody and T cell immunity after one dose which last for at least three months. The added multifunctional, dominant CD8+ T cell and Th1 CD4+ T cell responses offer a broad immune response profile which may provide optimal protection against COVID-19 disease. This, in combination with the simplicity in manufacturing and stability of DNA vaccines, substantiate the potential VB10.COV2 to serve as a second generation COVID-19 vaccine candidate. The ongoing development efforts and the knowledge we acquire will also support Vaccibody's more comprehensive efforts to establish a Disease X platform to more quickly respond to future threats from emerging pathogens."

The article entitled, "*Single dose immunization with a COVID-19 DNA vaccine encoding a chimeric homodimeric protein targeting receptor binding domain (RBD) to antigen-presenting cells induces rapid, strong and long-lasting neutralizing IgG, Th1 dominated CD4$^+$ T cells and strong CD8$^+$ T cell responses in mice",* has been published at the bioRxiv preprint server and may be found under the following link:
https://www.biorxiv.org/content/10.1101/2020.12.08.416875v1.

Webcast

Michael Engsig, CEO; Agnete Fredriksen, President & Chief Scientific Officer; and Director Infectious Diseases, Gunnstein Norheim, will host a webcast on Friday December 11, 2020 at 10 a.m. CET (9 a.m. GMT) to present Vaccibody's infectious disease strategy, as well as the SARS-CoV-2 preclinical data for the Company's vaccine product candidate, VB10.COV2. The webcast will be conducted in English and be followed by a Q&A session. The link for the webcast and the presentation will be available on Vaccibody's website:
https://www.vaccibody.com/financial-reports-and-presentations/.

About Vaccibody

Vaccibody AS, is a clinical-stage biopharmaceutical company, dedicated to the discovery and development of novel immunotherapies. The Company develops vaccines for the treatment cancer and infectious diseases. Vaccibody's vaccine technology specifically targets antigens to Antigen Presenting Cells, which are essential for inducing rapid, strong and long-lasting antigen-specific immune responses and elicit efficacious clinical responses. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is exclusively outlicensed to Genentech and is in phase I/IIa clinical trial for the treatment of melanoma, lung- , head and neck, renal-, and bladder cancer; and VB10.16, a therapeutic vaccine for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer and cancer of the

head & neck. The company has collaborations with Roche and Nektar Therapeutics within oncology.

Additionally, Vaccibody intends to leverage the potential of its platform in infectious disease indications.

Vaccibody's shares are traded on Euronext Growth Oslo, a trading platform operated by Euronext, the leading pan-European market infrastructure. The ticker code is VACC.

Further information about Vaccibody may be found at http://www.vaccibody.com

Contact for Vaccibody:

CEO Michael Engsig
Vaccibody AS
Cell: +45 6173 1509
mengsig@vaccibody.com

Vaccibody AS
Oslo Research Park
Gaustadalléen 21
0349 Oslo, Norway

Forward-looking Statements for Vaccibody

This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.